KWALITY PHARMA | CELESTIAL BIOLABS | KWALITY PHARMA/ CELESTIAL BIOLABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 32.8 | -11.0 | - | View Chart |
P/BV | x | 4.2 | 1.4 | 308.3% | View Chart |
Dividend Yield | % | 0.0 | 0.0 | - |
KWALITY PHARMA CELESTIAL BIOLABS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
KWALITY PHARMA Mar-24 |
CELESTIAL BIOLABS Mar-22 |
KWALITY PHARMA/ CELESTIAL BIOLABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 545 | NA | - | |
Low | Rs | 248 | NA | - | |
Sales per share (Unadj.) | Rs | 295.9 | 0.1 | 451,688.2% | |
Earnings per share (Unadj.) | Rs | 22.8 | -0.2 | -12,535.5% | |
Cash flow per share (Unadj.) | Rs | 41.6 | -0.2 | -24,792.0% | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 216.0 | 1.5 | 14,565.7% | |
Shares outstanding (eoy) | m | 10.38 | 22.59 | 45.9% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.3 | 0 | - | |
Avg P/E ratio | x | 17.4 | 0 | - | |
P/CF ratio (eoy) | x | 9.5 | 0 | - | |
Price / Book Value ratio | x | 1.8 | 0 | - | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 4,114 | 0 | - | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 305 | 1 | 24,766.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 3,072 | 1 | 207,548.6% | |
Other income | Rs m | 18 | 0 | - | |
Total revenues | Rs m | 3,090 | 1 | 208,785.1% | |
Gross profit | Rs m | 592 | -3 | -17,518.9% | |
Depreciation | Rs m | 196 | 0 | 65,196.7% | |
Interest | Rs m | 104 | 0 | 25,334.1% | |
Profit before tax | Rs m | 311 | -4 | -7,585.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 75 | 0 | - | |
Profit after tax | Rs m | 236 | -4 | -5,760.0% | |
Gross profit margin | % | 19.3 | -228.4 | -8.4% | |
Effective tax rate | % | 24.1 | 0 | - | |
Net profit margin | % | 7.7 | -276.7 | -2.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 2,427 | 43 | 5,696.9% | |
Current liabilities | Rs m | 1,519 | 53 | 2,843.6% | |
Net working cap to sales | % | 29.6 | -729.5 | -4.1% | |
Current ratio | x | 1.6 | 0.8 | 200.3% | |
Inventory Days | Days | 15 | 0 | - | |
Debtors Days | Days | 1,359 | 94,525 | 1.4% | |
Net fixed assets | Rs m | 1,515 | 129 | 1,172.8% | |
Share capital | Rs m | 104 | 226 | 45.9% | |
"Free" reserves | Rs m | 2,138 | -192 | -1,111.6% | |
Net worth | Rs m | 2,242 | 34 | 6,692.9% | |
Long term debt | Rs m | 196 | 85 | 230.5% | |
Total assets | Rs m | 3,942 | 172 | 2,294.7% | |
Interest coverage | x | 4.0 | -9.0 | -44.5% | |
Debt to equity ratio | x | 0.1 | 2.5 | 3.4% | |
Sales to assets ratio | x | 0.8 | 0 | 9,044.7% | |
Return on assets | % | 8.6 | -2.1 | -402.3% | |
Return on equity | % | 10.5 | -12.2 | -86.2% | |
Return on capital | % | 17.0 | -3.1 | -547.0% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 6.5 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 201 | NA | - | |
Fx inflow | Rs m | 1,383 | 0 | - | |
Fx outflow | Rs m | 212 | 0 | - | |
Net fx | Rs m | 1,172 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 430 | -3 | -15,630.2% | |
From Investments | Rs m | -264 | NA | 659,925.0% | |
From Financial Activity | Rs m | -174 | 3 | -6,717.4% | |
Net Cashflow | Rs m | -8 | 0 | 4,060.0% |
Indian Promoters | % | 54.8 | 26.1 | 210.3% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 45.2 | 73.9 | 61.1% | |
Shareholders | 7,487 | 12,523 | 59.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare KWALITY PHARMA With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | KWALITY PHARMA | CELESTIAL BIOLABS | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.72% | -4.72% | -0.51% |
1-Month | 14.36% | -23.48% | -1.45% |
1-Year | 131.78% | -65.59% | 44.29% |
3-Year CAGR | 6.79% | -57.44% | 18.87% |
5-Year CAGR | 107.83% | -50.28% | 25.62% |
* Compound Annual Growth Rate
Here are more details on the KWALITY PHARMA share price and the CELESTIAL BIOLABS share price.
Moving on to shareholding structures...
The promoters of KWALITY PHARMA hold a 54.8% stake in the company. In case of CELESTIAL BIOLABS the stake stands at 26.1%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of KWALITY PHARMA and the shareholding pattern of CELESTIAL BIOLABS.
Finally, a word on dividends...
In the most recent financial year, KWALITY PHARMA paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of 0.0%.
CELESTIAL BIOLABS paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of KWALITY PHARMA, and the dividend history of CELESTIAL BIOLABS.
For a sector overview, read our pharmaceuticals sector report.
After starting the day on a flattish note with a positive bias, the benchmarks showcased heightened volatility and ended the day weak.